PRA consolidates in Poland to support growth, contain costs

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Food and drug administration Europe

PRA has relocated its Poland-based early development services and product registration teams into a larger shared office after achieving “solid increases in the placement of clinical studies”.

Consolidating both teams in the same larger, more modern office in Warsaw, Poland will accommodate continuing growth, improve internal and external communications and support “cost containment for shared services​”.

PRA Phase I to IV trials in Poland are “achieving high patient recruitment and accessing excellent quality data​”, Susan Stansfield, executive vice president (EVP), product registration, Europe, Africa and Asia-Pacific, told Outsourcing-Pharma.

Solid increases in the placement of clinical studies​” have been achieved, said Stansfield, with PRA experiencing “growth rates ahead of the market​”. PRA “fully expects​” growth in Poland to continue, citing European Medicines Agency (EMA) data​ as evidence of the market’s strength.


In Poland PRA provides feasibility, site start-up, site management and monitoring of Phase I to IV clinical trials. This is supported by medical affairs, project management and quality assurance services.

Special patient groups are accessed for specific Phase I needs. This is handled by the early development services team who establish Phase I study environments within central medical facilities that specialise in treating target patient populations.

Future expansion

Geographic expansion at PRA is underpinned by a patient-driven medical informatics technology. Using the system PRA can “estimate potential patient access that would result from moving into new territories and expanding in existing ones​”, said Stansfield.

We expect to see further growth in Eastern Europe, Middle East and Africa, Asia and Latin America​”, said Stansfield, and PRA is “growing and consolidating in these regions, opening new facilities to house our staff as appropriate​”.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more